These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33616727)

  • 21. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database.
    Cutroneo PM; Isgrò V; Ientile V; Santarpia M; Ferlazzo G; Fontana A; Carrega P; Matarangolo E; Barnaba S; Spina E; Trifirò G
    Br J Clin Pharmacol; 2021 Feb; 87(2):527-541. PubMed ID: 32495965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insights from Pharmacovigilance: Gastrointestinal-Related Immune Checkpoint Inhibitor Adverse Events.
    Reese SW; Marchese M; McNabb-Baltar J
    Gastroenterology; 2020 Oct; 159(4):1195-1200.e1. PubMed ID: 32681919
    [No Abstract]   [Full Text] [Related]  

  • 24. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors.
    Park H; Hatabu H; Ricciuti B; Aijazi SJ; Awad MM; Nishino M
    Eur J Radiol; 2020 Nov; 132():109275. PubMed ID: 32949913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
    Ma Z; Pei J; Sun X; Liu L; Lu W; Guo Q; Lyu J; Liu Y; Zhang Y; Zhao Z
    Front Pharmacol; 2021; 12():663088. PubMed ID: 34276364
    [No Abstract]   [Full Text] [Related]  

  • 27. Gastrointestinal toxicities associated with immune checkpoint inhibitors: a disproportionality analysis leveraging VigiBase, the WHO Adverse Drug Reaction Database.
    Huang S; Bai X; Fang T; Guo Y; Zheng K; Lin X
    J Zhejiang Univ Sci B; 2021 Feb; 22(2):156-164. PubMed ID: 33615756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.
    Nguyen LS; Ortuno S; Lebrun-Vignes B; Johnson DB; Moslehi JJ; Hertig A; Salem JE
    Eur J Cancer; 2021 May; 148():36-47. PubMed ID: 33721705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ear and labyrinth toxicities induced by immune checkpoint inhibitors: a disproportionality analysis from 2014 to 2019.
    Hu F; Ye X; Zhai Y; Xu J; Guo X; Guo Z; Zhou X; Ruan Y; Zhuang Y; He J
    Immunotherapy; 2020 May; 12(7):531-540. PubMed ID: 32456497
    [No Abstract]   [Full Text] [Related]  

  • 30. The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations.
    Chiang CH; Chiang CH; Ma KS; Hsia YP; Lee YW; Wu HR; Chiang CH; Peng CY; Wei JC; Shiah HS; Peng CM; Neilan TG
    Jpn J Clin Oncol; 2022 Dec; 52(12):1389-1398. PubMed ID: 36208180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
    Yin B; Xiao J; Li J; Liu X; Wang J
    J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
    Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
    Wang H; Guo X; Zhou J; Li Y; Duan L; Si X; Zhang L; Liu X; Wang M; Shi J; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):191-197. PubMed ID: 31762218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach.
    de La Rochefoucauld J; Noël N; Lambotte O
    Intern Emerg Med; 2020 Jun; 15(4):587-598. PubMed ID: 32144552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrotoxicity of Immune Checkpoint Inhibitors: A Disproportionality Analysis from 2013 to 2020.
    Qu J; Ding Y; Jiang K; Hao J; Li Y; Zhang A; Li Z; Qi G; Xu Z; Liu X; Ma J; Bi K; Li Z
    Tohoku J Exp Med; 2021 Aug; 254(4):275-282. PubMed ID: 34433731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance system.
    Cui X; Yan C; Xu Y; Li D; Guo M; Sun L; Zhu Z
    Cancer Med; 2023 Mar; 12(5):5181-5194. PubMed ID: 36504294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint inhibitor-associated capillary leak syndrome: A systematic review and a worldwide pharmacovigilance study.
    Wong So J; Bouibede F; Jonville-Béra AP; Maillot F; Barbier F; Largeau B
    J Intern Med; 2023 Jul; 294(1):58-68. PubMed ID: 37038359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.
    Le TK; Brown I; Goldberg R; Taylor MT; Deng J; Parthasarathy V; Bordeaux ZA; Alphonse MP; Kwatra MM; Naranbhai V; Gusev A; Alhariri J; LeBoeuf NR; Reynolds KL; Cappelli LC; Naidoo J; Brahmer JR; Kang S; Semenov YR; Kwatra SG
    J Invest Dermatol; 2022 Nov; 142(11):2896-2908.e4. PubMed ID: 35605659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program.
    Jimenez J; Gwillim EC; Kosche C; Figueiredo A; Rauck C; Rangel SM; Choi J; West DP; Nardone B; Lacouture ME
    J Am Acad Dermatol; 2020 Sep; 83(3):955-957. PubMed ID: 32014533
    [No Abstract]   [Full Text] [Related]  

  • 40. Pulmonary tuberculosis associated with immune checkpoint inhibitors: a pharmacovigilance study.
    Zhu J; He Z; Liang D; Yu X; Qiu K; Wu J
    Thorax; 2022 Jul; 77(7):721-723. PubMed ID: 35277447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.